{"entity":{"id":"nct04585035","kind":"trial","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Garsorasib, Cetuximab and Pembrolizumab in non-small-cell lung cancer, run by InventisBio Co., Ltd, active and no longer recruiting.","summary":"Study to Evaluate D-1553 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT04585035 by InventisBio Co., Ltd, with 180 participants enrolled, started 2020-10-02 and due to reach its primary completion in 2024-04-30. Interventions recorded: D-1553 and D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04585035","url":"https://clinicaltrials.gov/study/NCT04585035"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","kras-g12c-nsclc"],"sections":[],"technologies":["kinase-inhibitors","kras-inhibitors"],"targets":[],"drugs":["garsorasib","cetuximab","pembrolizumab"],"companies":["inventisbio","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04585035-signal-transduct-target-ther-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04585035","phase":"1/2","setting":"A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation","sponsor":"InventisBio Co., Ltd","started":"2020-10-02","startedType":"actual","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04585035/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"paper":[{"id":"paper-nct04585035-signal-transduct-target-ther-2025","kind":"paper","name":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","route":"/key-papers/paper-nct04585035-signal-transduct-target-ther-2025/"}]}}